Lilly(LLY)
Search documents
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
The Motley Fool· 2024-06-15 18:05
The company has too many weapons at its disposal.Developing brand-new drugs is a long and expensive process that doesn't always deliver a positive return on investment. Occasionally, some pharmaceutical companies hit the jackpot and launch medicines worth all that trouble. That's what Eli Lilly (LLY -0.55%) has on its hands with tirzepatide, marketed as Mounjaro in the diabetes market and as Zepbound to help with weight loss. Analysts predict that tirzepatide's peak sales could reach $25 billion, but to get ...
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
The Motley Fool· 2024-06-15 11:15
The drugmaker continues to make headlines for all the right reasons.Eli Lilly's (LLY -0.55%) name has become somewhat synonymous with its work in diabetes and obesity care. That's understandable. The drugmaker is a leader in these areas, and its most recent medicines, Mounjaro and Zepbound, promise to rack up impressive sales.That said, there is much more to Eli Lilly than its successful efforts in these areas. The company has been looking to break into another challenging field: Alzheimer's disease (AD). E ...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
The Motley Fool· 2024-06-15 10:50
Want peace of mind about your investments? Consider these great stocks.Have you ever felt anxiety about clicking the final button to buy a stock? Some investors agonize over their decisions. It doesn't have to be that way, though, if you find the right stocks.Three Motley Fool contributors believe they've identified good picks -- and they're all big biotech stocks. Here's why they think Eli Lilly (LLY -0.55%), Novo Nordisk (NVO 0.01%), and Vertex Pharmaceuticals (VRTX 0.35%) are growth stocks you can buy ri ...
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
ZACKS· 2024-06-14 16:25
The lucrative Alzheimer’s disease market could have a second player soon, posing strong competition to Biogen (BIIB) and its Japan-based partner Eisai’s Leqembi, approved last year in the United States to reduce the cognitive decline associated with early Alzheimer’s disease.On Jun 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly’s (LLY) Alzheimer's disease drug, donanemab.The committee said that data from clin ...
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
The Motley Fool· 2024-06-14 09:50
Novo Nordisk's competition in the obesity drug market is heating up.Novo Nordisk's (NVO -0.54%) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping position is precarious. Here are three drugs most likely to dethrone Novo Nordisk's blockbuster drug.1. Eli Lilly's Zepbound/MounjaroEli Lilly (LLY 1.85%) won U.S. regulatory approval for Ze ...
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
ZACKS· 2024-06-13 15:18
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside t ...
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
ZACKS· 2024-06-12 15:26
The lucrative Alzheimer’s disease market could have a second player soon, posing strong competition to Biogen (BIIB) and its Japan-based partner Eisai’s Leqembi, approved last year in the United States to reduce the cognitive decline associated with early Alzheimer’s disease.On Jun 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly’s (LLY) Alzheimer's disease drug, donanemab.The committee said that data from clin ...
高盛:礼来公司(LLY)第45 届医疗保健大会主要
观点指数· 2024-06-12 02:07
更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 10 June 2024 | 1:39PM EDT Eli Lilly & Co. (LLY): 45th Annual Global Healthcare Conference— Key Takeaways Chris Shibutani, M.D. +1(617)204-2437 | chris.shibutani@gs.com Goldman Sachs & Co. LLC Karishma Raghuram +1(212)357-6408 | karishma.raghuram@gs.com Goldman Sachs & Co. LLC Participants: Patrik Jonsson (EVP & President, Lilly Diabetes and Obesity and Lilly USA); Jeffrey Emmick (SVP, Lilly Product Development) Bottom Line: We hosted an investor breakfast with the President of E ...
Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Seeking Alpha· 2024-06-11 18:24
StockCharts.com Last week I wrote an update on the largest overall holding at my firm, Eli Lilly and Company (NYSE:LLY), in an article titled, "Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?" Following strong earnings, approval of its blockbuster diabetes drug Mounjaro for weight loss, and a growing demand for weight loss drug solutions, I raised my 5-year target price to $1,455. This update was based on a very conservative projected growth rate of 19% per year and a multiple that I feel Li ...
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Benzinga· 2024-06-11 18:19
Loading...Loading...BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company LLY, with a price forecast of $1,000.An advisory committee to the U.S. Food and Drug Administration (FDA) delivered a favorable verdict on the company’s Alzheimer’s treatment, donanemab, declaring its benefits to surpass the associated risks.The outcome will support regulatory approval of donanemab in patients with mild cognitive impairment/mild dementia, Meacham writes.Moreover, regarding tau strati ...